Moleculin reports positive Annamycin AML trial: median OS 15 mos for CR, 12 mos for 2L

Moleculin Biotech, Inc.

Phase 1b/2 MB-106 trial completed; median OS 15 months for complete remissions (n=8), 12 months for 2L efficacy evaluable (n=9).
Median OS for ITT population (1L-7L) was 9 months, exceeding typical 4-6 months for relapsed AML.
CR rate 36% ITT, 50% in 2L; 50% of CR subjects proceeded to bone marrow transplant; no cardiotoxicity.
Database lock expected Sep 2025; final clinical study report in Q1 2026; Phase 3 MIRACLE trial enrolling first 45 pts.
Authorized common shares increased from 100M to 500M effective Aug 21, 2025.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

Moleculin Biotech, Inc.: Stockholders approved a Certificate of Amendment to increase authorized common stock from 100,000,000 to 500,000,000 shares, effective upon filing with the Delaware Secretary of State on August 21, 2025 (effective 2025-08-21).

Change: charter amendment
Effective: 2025-08-21

Exact text from the filing

As previously disclosed, at the Moleculin Biotech, Inc. (the “Company”) annual meeting of stockholders held on August 18, 2025, the Company’s stockholders approved, among other matters, a proposal to approve a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate Amendment”) which would amend the Company’s existing certificate of incorporation, as amended, to increase the number of authorized shares of the Company’s common stock from 100,000,000 shares to 500,000,000 shares.

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-027798

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.